PrEP - Pre-exposure prophylaxis
Feb 14, 2023
Authors: Jill Hanass-Hancock, Nonhlonipho Bhengu, Theresa Exner, Slindile Magusthwa, Abigail Harrison, Curtis Dolezal, Lori Miller, Laurie Bauman, Susie Hoffman Abstract: This article describes the processes of transforming an in-person group-based intervention to...
Nov 15, 2022
RECORDED: November 15, 2022, 9:00 am – 10:00 am EST Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls As regulatory approvals for long-acting, injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) against HIV move forward,...
Nov 15, 2022
Abstract:Â Introduction:Â Male clients (MCs) are integral to sex work-driven HIV transmission dynamics as sexual partners of female sex worker (FSW). MCs contribute disproportionately to incident HIV globally and in sub-Saharan Africa, with 27% of new infections...
Sep 28, 2022
Article and Study Summary: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Published in: N Engl J Med. 2022;387(9):810-823 Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Authors: Conradie F, Bagdasaryan TR, Borisov...
Aug 10, 2022
Abstract: In 2021, long-acting cabotegravir (LA CAB) was approved by the United States Food and Drug Administration for an indication of pre-exposure prophylaxis in women. This is a first in what is hoped to be a robust pipeline of long-acting antiretroviral agents...